Filing Details
- Accession Number:
- 0001209191-18-022004
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-03-28 21:12:26
- Reporting Period:
- 2018-03-26
- Accepted Time:
- 2018-03-28 21:12:26
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1628738 | Audentes Therapeutics Inc. | BOLD | Biological Products, (No Disgnostic Substances) (2836) | 461606174 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1679129 | Suyash Prasad | C/O Audentes Therapeutics, Inc. 600 California Street, 17Th Floor San Francisco CA 94108 | Senior Vp & Chief Med Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-03-26 | 1,900 | $0.79 | 1,900 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-03-26 | 1,900 | $30.00 | 0 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2018-03-27 | 300 | $0.79 | 300 | No | 4 | M | Direct | |
Common Stock | Disposition | 2017-03-27 | 300 | $30.00 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2018-03-26 | 1,900 | $0.00 | 1,900 | $0.79 |
Common Stock | Stock Option (right to buy) | Disposition | 2018-03-27 | 300 | $0.00 | 300 | $0.79 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
78,970 | 2024-02-18 | No | 4 | M | Direct | |
78,670 | 2024-02-18 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date.